Fresh analysis suggests that individuals who come off popular GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who halt conventional lifestyle regimens.
Research printed in a major health publication shows that while obese individuals often shed substantial amounts of their body weight while using the jabs, the mass is regained at an average rate of 0.8 kg per month after stopping.
"People purchasing these treatments must be cognizant of the danger of fast weight regain when the therapy concludes," warns lead investigator Dr. Susan Jebb.
This pace of recovery implies a reversion to starting mass in about 18 months.
Analyzing Treatments
The study, which examined dozens of trials involving thousands of patients, compared the outcomes of GLP-1 agonists with conventional dieting.
Researchers emphasize that individuals who shed pounds through lifestyle changes alone typically have a more gradual weight regain—perhaps 0.1 kg a month—post-intervention.
Explaining the Fast Regain
Doctors suggest the mode of action of the jabs is key to understanding the amplified weight return.
These medications mimic a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Artificially providing GLP-1 concentrations several times higher than the body's typical production might result in the body to generate a reduced amount of its endogenous GLP-1, and may also diminish sensitivity to its actions," explained Dr. Adam Collins, a nutrition expert.
"Stopping of this hormone supplement leads to hunger is uncontrolled, making overeating much more probable."
A Chronic Disease?
Medical guidelines suggest the jabs for people with weight-linked medical conditions, accompanied by recommended lifestyle changes.
Many experts argue that, given the high risk of relapse, the therapy might need to be life-long.
This view is supported by drug manufacturers, who note that the findings "highlight the long-term character of obesity," akin to managing diseases like hypertension.
Patient Accounts
Users who have discontinued the medication explain a powerful return of hunger.
"It was like a switch that goes on and I was suddenly extremely hungry," described a patient.
This difficulty is compounded if individuals have not developed lasting dietary or behavioural changes during treatment.
Widespread Interest
Recent estimates indicate that millions of people in the UK have tried these injections in the past year, with desire continuing to grow.
- Use is higher among females compared to men.
- The 40s and 50s age group shows the highest usage rates.
- Many obtain the medications through private healthcare rather than the NHS.
Finally, clinicians emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a permanent cure and lasting health benefits hinges on combined behavioural management.
